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Effects of estrogens on cardiovascular structure in uninephrec-
tomized SHRsp rats.
Background. The risk of cardiovascular disease in uremic pa-
tients is greater in male than in female patients. Estrogens seem
to play a cardioprotective role until menopause. Experimental
data on the effect of estrogens on cardiovascular damage are
controversial and potential underlying mechanisms especially
in renal failure have not been fully clarified.
Methods. Three-month-old female uninephrectomized
stroke-prone spontaneously hypertensive (SHRsp) rats were
sham-operated or ovariectomized. Subsequently, they received
either vehicle (sesame oil) or 17-b-3 benzoate estradiol
(E2) (25 lg/day) or estriol (E3) (0.02 mg/day), respectively.
After 3 months the animals were sacrified and the organs
were harvested using pressure-controlled perfusion fixation.
Stereologic parameters such as capillary length density (LV),
mean intercapillary distance (MID), and volume density of
the interstitial tissue (Vv) were quantitated. Additionally,
expression of transforming growth factor-b (TGF-b), vascular
endothelial growth factor (VEGF), flt-1, endothelial nitric
oxide synthase (eNOS), endothelin-1 (ET-1), endothelin A
receptor (ETA) receptor, and a estrogen receptor was assessed
using immunohistochemistry. Intramyocardial capillaries and
the aorta were investigated by morphometric methods.
Results. LV (mm/mm3) was significantly lower (2421 ± 500)
and MID (lm) significantly higher (22.2 ± 2.33) in vehicle-
treated uninephrectomized/ovariectomized compared to
uninephrectomized/sham-ovariectomized controls (LV 3629 ±
960, MID 12.7 ± 2.7) as well as estradiol (LV 3340 ± 739,
MID 12.1 ± 4.96) and estriol (LV 4655 ± 618, MID 14.2 ±
2.89) treated uninephrectomized/ovariectomized animals.
The volume density of the cardiac interstitium was higher in
vehicle-treated uninephrectomized/ovariectomized animals
compared to uninephrectomized/sham-ovariectomized, estra-
diol and estriol treated uninephrectomized/ovariectomized
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rats. The protein level expression of TGF-b was higher in
vehicle treated uninephrectomized/ovariectomized compared
to uninephrectomized/sham and all treatment groups.
Conclusion. In ovariectomized SHRsp rats with moderate
renal failure cardiac lesions were strikingly less after estradiol
or estriol treatment. The results document a beneficial role of
estrogens on cardiac abnormalities in a model of moderate renal
dysfunction.
Estrogens exhibit several biologic actions that may ac-
count for their cardiovascular benefit, including favorable
effects on the lipid profile, antioxidant activity, enhanced
fibrinolysis, and direct actions on the vasculature [1].
The incidence of coronary heart disease dramatically in-
creases after menopause [2]. Extensive epidemiologic
observations had suggested that postmenopausal hor-
mone replacement therapy confers cardiovascular ben-
efit [3, 4]. Recent evidence from controlled trials [5–8]
suggests, however, in contrast to observational studies [3,
4], that hormone replacement therapy is associated with
increased cardiac events. Apparently, once cardiovascu-
lar lesions have been established, estrogens no longer pre-
vent further progression [5, 7, 9].
In patients with renal disease cardiovascular risk is
extremely elevated. The underlying pathophysiology is
complex [8]. Some potential pathogenetic pathways such
as the renin-angiotensin system [10], the endothelin
system [11, 12], and cellular Ca2+ overload [13] are in-
fluenced by estrogens. Therefore, elucidation of the car-
diovascular effects of estrogens is of potential relevance
for understanding the cardiac problems in renal disease.
The effects of ovarian function on the cardiovascu-
lar system are largely mediated by 17b-estradiol and its
metabolites [14, 15]. The two estrogen receptors, ERa
and ERb [16], are expressed in cell types involved in
atherogenesis, including endothelial cells and vascular
smooth muscle cells (VSMCs) [17].
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To further address potential cardioprotective effects of
estrogens in renal disease we investigated the effects of
estrogen in a model of renal insufficiency due to an in-
crease in intraglomerular pressure (i.e., the uninephrec-
tomized spontaneously hypertensive stroke-prone rat
(SHRsp). We investigated the effects of two estrogens,
17-b-3-benzoate estradiol and estriol, respectively, on
structural parameters of heart and aorta using stereologic
methods.
METHODS
Animals
Three-month-old female SHRsp were obtained from
Professor U. Ganten (MDC Berlin, Germany) and were
housed in box cages under standard conditions (light on
from 08:00 to 20:00; 40% to 70% relative humidity, 22
± 1◦C). All animals had free access to water and chow
(soy-free, phytoestrogen-poor Altromin 1324) (Lage,
Germany) (1%, NaCl). These animals develop sponta-
neously severe hypertension, malignant nephrosclerosis,
and stroke [18].
Animals were randomly alloted to the different exper-
imental groups. In the experimental animals both ovaries
were resected (ovariectomized); and to enhance kidney
pathology in all animals the right kidney was removed
(uninephrectomized) under general anesthesia. Animals
received 17-b-3-benzoate estradiol (25 lg/day) (Aldrich
Chemical Co., Milwaukee, WI, USA) dissolved in sesame
oil (Sigma Co., Steinheim, Germany) by daily subcuta-
neous injection or estriol in the drinking water designed
to deliver a daily dose of 0.02 mg/day (Incurin; Intervet
Pharma, Angers, France) (courtesy Dr. Rutten). Water
consumption was measured and the doses of the estriol
in the drinking water were adjusted. The control animals
received the vehicle sesame oil subcutaneously.
Experimental protocol
The rats were randomly allocated to the following
five experimental groups: (1) uninephrectomized/sham-
ovariectomized + vehicle (N = 9); (2) uninephrecto-
mized/sham-ovariectomized + 17-b-3-benzoate estradiol
(N = 10); (3) uninephrectomized + ovariectomized +
vehicle (N = 10); (4) uninephrectomized + ovariec-
tomized + 17-b-3-benzoate estradiol (N = 11); and (5)
uninephrectomized + ovariectomized +estriol (N = 9).
Body weight and systolic blood pressure (by tail
plethysmography) were measured at regular intervals.
Perfusion fixation and tissue sampling
Twelve weeks after the second operation the experi-
ment was terminated by retrograde perfusion fixation.
The abdominal aorta was catheterized under ketamine/
diazepam anesthesia, and blood samples were taken
for determination of blood hemoglobin concentration
and plasma chemistry. The viscera were rinsed with
a 10% dextran solution containing 0.5 g/L procain-
hydrochloride for 2 minutes. Ten seconds after starting
the aortic perfusion, the vena cava was incised to drain
the blood. After dextran infusion, the vascular system
was perfused with 0.2 mol/L phosphate buffer containing
3% glutaraldehyde for 12 minutes.
After the perfusion, the heart, aorta, and uterus of each
animal were taken out. The heart and left ventricular
weight and volume were determined. Tissue samples and
sections were obtained and stained according to the ori-
entator method [19]. Uniformly random sampling of the
myocardium was achieved by preparing a set of equidis-
tant slices of the left ventricle and the interventricular
septum with a random start. Two slices were selected by
area weighted sampling and processed accordingly. Eight
pieces of the left ventricular muscle, including the sep-
tum were prepared and afterwards embedded in Epon-
Araldite. Semithin sections (0.8 lm) were stained with
methylene-blue and basic fuchsin and examined by light
microscopy with oil immersion and phase contrast at a
magnification of 1000:1. A 1 mm thick section of the aorta
thoracica descendens was cut perpendicular to the vessel
axis, and embedded and sectioned as described above.
Estradiol and testosterone plasma concentrations
Estradiol plasma concentrations were measured with
an analytic system (Elecsys 2010) (Roche, Mannheim,
Germany) [20]. Testosterone plasma concentrations were
evaluated by radioimmunoassay with 125iodine [21].
Morphologic investigations
All investigations were performed in a blinded man-
ner (i.e., the observer was unaware of the animal’s study
group). Stereologic analysis was performed on eight ran-
dom samples of differently orientated sections of the left
ventricular myocardium per animal according to the ori-
entator method. Length density (LV) of capillaries, that
is, the length of capillaries per unit tissue volume, and
the volume density (VV) of cardiac capillaries, defined as
the volume of capillaries per unit myocardial tissue vol-
ume, were measured in eight systematically subsampled
areas per section using a Zeiss eyepiece with 100 points
for point counting. The length density of myocardial cap-
illaries (LV) was determined using the equation LV = 2
QA where QA is area density, for example, the number
of capillary transects per area of myocardial reference
tissue. Total capillary length per heart was calculated us-
ing the volume of the left ventricle (V) according to the
formula L = LV × V. Intercapillary distance (i.e., the
distance between the centers of two adjacent intramy-
ocardial capillaries) was calculated according to a modifi-
cation of the formula of Henquell and Honig as described
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Table 1. Animal data (at the end of the experiment)
Stroke-prone Body Systolic blood Daily food Albuminuria Heart Left ventricular Uterus
spontaneously hypertensive weight g pressure mm Hg consumption g mg/24 hours weight mg weight mg weight g
Uninephrectomy, sham ovariectomy +
vehicle (N = 9)
217 ± 9 191 ± 17 24 ± 4 1.10 ± 0.46a 1010 ± 85a,b 900 ± 61a 1.15 ± 0.2a
Uninephrectomy, sham ovariectomy +
17-b-3-benzoate estradiol (N = 10)
191 ± 7b 191 ± 24 24 ± 7 1.12 ± 0.53a 1040 ± 17a 826 ± 88a 1.32 ± 0.22a
Uninephrectomized/ovariectomized +
vehicle (N = 10)
203 ± 9b 192 ± 23 23 ± 4 25.4 ± 8.52 1183 ± 39b 1027 ± 239b 0.49 ± 0.14
Uninephrectomy/ovariectomy +
17-b-3-benzoate estradiol (N = 11)
192 ± 7b 209 ± 17 15 ± 4a,b 15.4 ± 6.12a 1087 ± 35a 875 ± 68 0.89 ± 0.19a
Uninephrectomy/ovariectomy + estriol
(N = 9)
235 ± 13 178 ± 21 24 ± 3 6.54 ± 2.24a,b 966 ± 79a 796 ± 74 0.74 ± 0.14a
Analysis of variance (ANOVA) P < 0.05 NS P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05
aP < 0.05 vs. uninephrectomy/ovariectomy + vehicle; bP < 0.05 vs. uninephrectomy/ovariectomy + estriol; cP < 0.05 vs. uninephrectomy/ovariectomy +
17-b-3-benzoate estradiol.
previously by Gross et al [19]. Volume density (VV) of
the capillaries, interstitial tissue, and myocytes was ob-
tained using the point counting method according to the
equation PP = VV where PP is point density. Reference
volume was the total myocardial tissue (exclusive of non-
capillary vessels, that is, arterioles and veins). Vascular
geometry of intramyocardial arteries and of the aorta
(i.e., wall thickness, lumen diameter, media and lumen
area) was analyzed using a semiautomatic image analysis
system (Videoplan) (Kontron Co., Eching, Germany) as
described in detail [22].
Immunhistologic investigation
Because estrogens influence vascular endothelial
growth factor (VEGF) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), protein expression of VEGF (:25)
and its receptor Flt-1 (R&D Systems, Minneapolis,
MN, USA) (1:25), and endothelial nitric oxide synthase
(eNOS) (A&R via Dinova, Hamburg, Germany) (1:200)
were investigated on parraffins sections. Additionally,
we analyzed the protein expression of the a-estrogen
receptor (Santa Cruz Biotechnology) (1:50). Immunohis-
tologic stains using antibody against endothelin-1 (ET-
1) (a-ET-1 polyclonal rabbit) (Biotrend, Cologne, Ger-
many) (1:50) and ET-A receptor (sheep ETRA) (Bio
Trend) (1:50) were also performed and investigated.
Since ET-1 and transforming growth factor-b (TGF-b)
influence each other, the expression of TGF-b (TGF-
b1 poyclonal rabbit) (Santa Cruz Biotechnology) was
analyzed. Two independent investigators masked to the
different experimental animal groups performed semi-
quantitative scoring as described in detail [23].
Semiquantitative reverse transcription-polymerase chain
reaction (RT-PCR) for cardiac ET-1 and TGF-b mRNA
expression
Total RNA (1 lg) was dissolved in 20 lL of a re-
action mixture containing 4 mmol/L deoxyadenosine
triphosphate (dATP), 32P deoxycytidimine triphos-
phate (dCTP), dTTP, and deoxyguanosine triphos-
phate (dGTP); 10 U RNAsin (Life Technologies BLR,
Grand Island, NY, USA); 100 pmol random hexamers
(Boehringer Mannheim GmbH, Mannheim, Germany);
PCR buffer [final concentrations 1.6 mmol/L (NH4)2SO4,
2.0 mmol/L Tris-HCl (pH 8.4), and 1.5 mmol/L MgCl2];
and 100 U Superscript reverse transcriptase (Life Tech-
nologies BLR). After incubation at 42◦C for 45 minutes,
the enzyme was denatured for 5 minutes at 94◦C. Semi-
quantification of ET-1 and TGF-b mRNA was carried out
using deletion mutants of the ET-1 and TGF-b cDNA as
internal standard. The amplifications of the mutants re-
sulted in PCR products of 300 bp for ET-1 and 302 bp
for the TGF-b . The mutant cDNAs were added to the
PCR mixture after RT to complete with the endogenous
ET-1 0.4 pg of the plasmid was added to the PCR mix-
ture per sample and for TGF-b 0.05 pg. The PCR prod-
ucts were separated in a 3% metaphorgel and scanned as
TIF data. The quotient of measured endogenous sample
and aquivalent mutant was calculated by Scion-Image-
program (National Institutes of Health, Bethesda, MD,
USA).
Statistics
Data are given as mean ± SD. After testing for normal
distribution the Kruskal-Wallis test or one-way analysis
of variance (ANOVA) were chosen for analysis of vari-
ance, followed by Duncan’s multiple-range test to test for
differences between groups. The results were considered
significant when the probability of error (P) was less than
0.05.
RESULTS
Animal data
In uninephrectomized/ovarietomized administration
of 17-b-3-benzoate estradiol, but not of estriol, was as-
sociated with decreased food consumption (Tables 1
to 3). There were no significant differences of body
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Table 2. Plasma biochemistry (at the end of the experiment)
HDL LDL 17-b-
Creatinine Cholesterol Triglyceride cholesterol cholesterol 3-benzoate Testosterone
mg/dL mg/dL mg/dL mg/dL mg/dL estradiol pg/mL ng/dL
Uninephrectomy/sham
ovariectomy + vehicle (N = 9)
0.55 ± 0.18a 107 ± 14.6a,b,c 69 ± 17.04b 64 ± 5.96a,c 29 ± 12.78a,b 13 ± 9.23b,d 16.0 ± 6.6a,b,c
Uninephrectomy/ham
ovariectomy + estradiol (N =
10)
0.48 ± 0.06a,b 107 ± 16.3a,b,c 84 ± 25.3b 61 ± 8.31a,b,c 29 ± 12.64a,b 102 ± 60 20.5 ± 5.7a,b,c
Uninephrectomy/ovariectomy +
vehicle (N = 10)
0.68 ± 0.15 148 ± 24.0 74 ± 32.4b 88 ± 11.7 45 ± 11.9 8 ± 5.1b,d 6.0 ± 2.8
Uninephrectomy/ovariectomy +
estradiol (N = 11)
0.60 ± 0.09 143 ± 31.3 117 ± 30.2 72 ± 18.3 48 ± 18.3 101 ± 94.4 9.3 ± 4.13
Uninephrectomy/ovariectomy +
estriol (N = 9)
0.53 ± 0.06a 133 ± 16.3 75 ± 21.3b 83 ± 6.62 35 ± 14.7 11 ± 3.9b,d 5.6 ± 2.78
Analysis of variance (ANOVA) P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05
aP < 0.05 vs. uninephrectomy/ovariectomy + vehicle; bP < 0.05 vs. UNX/OVX + 17-b-3-benzoate estradiol; cP < 0.05 vs. uninephrectomy/ovariectomy + estriol; dP
< 0.05 vs. sham + 17-b-3-benzoate estradiol.
Table 3. Stereologic analysis of the heart
Capillary length density Volume density Mean intercapillary VV of nonvascular
(LV) mm2/mm3 of capillaries (Vv)% distance lm interstitial tissue%
Uninephrectomy/sham ovariectomy +
vehicle (N = 9)
3629 ± 960a 12.7 ± 2.7a 18.2 ± 2.12a 1.75 ± 0.07a
Uninephrectomy/sham ovariectomy +
17-b-3-benzoate estradiol (N = 10)
3603 ± 512a 14.2 ± 3a 18. ± 1.38a 1.85 ± 0.03a
Uninephrectomy/ovariectomy + vehicle
(N = 10)
2421 ± 500b,c 10.7 ± 1.1b,c 22.2 ± 2.33b,c 2.89 ± 0.02b,c
Uninephrectomy/ovariectomy +
17-b-3-benzoate estradiol (N = 11)
3340 ± 739a 12.1 ± 0.96a 18.9 ± 2.25a 1.84 ± 0.04a
Uninephrectomy/ovariectomy + estriol
(N = 9)
4655 ± 618a 14.2 ± 2.89a 15.8 ± 1.02a,b 1.85 ± 0.07a
Analysis of variance (ANOVA) P < 0.05 P < 0.05 P < 0.05 P < 0.05
aP < 0.05 vs. uninephrectomy/ovariectomy + vehicle; bP < 0.05 vs. uninephrectomy/ovariectomy + 17-b-3-benzoate estradiol; cP < 0.05 vs. uninephrec-
tomy/ovariectomy + estriol.
weight between the five groups with the exception
of higher body weight in estriol treated uninephrec-
tomized/ovariectomized animals. The weight of the
heart was significantly higher in uninephrectomized/
ovariectomized + vehicle compared to sham-ovariecto-
mized animals and to both estrogen intervention groups.
The weight of the perfusion-fixed uteri as an index of es-
trogen effect was significantly lower in vehicle-treated
uninephrectomized/ovariectomized animals compared
to the other experimental groups.
There were no significant differences of systolic
blood pressure between the groups. After uninephrec-
tomy/ovariectomy a striking increase of urinary albumin
excretion was observed compared to controls and treated
groups.
Plasma concentrations of 17-b-3-benzoate estradiol
were obviously higher in 17-b-3-benzoate estradiol-
treated sham-ovariectomized and uninephrectomized/
ovariectomized animals (detection threshold was 7 pg/
mL). The estriol concentrations were measured, but were
low so that the detection threshold (analytic sensitivity
0.03 lg/mL) was not consistently transgressed (data not
shown). Testosterone concentrations were significantly
(P < 0.05) lower after ovariectomy (within the limits of
the assay) and not further modified by estrogen adminis-
tration.
Creatinine and urea concentrations were significantly
higher in uninephrectomized/ovariectomized + vehicle-
treated compared to ovariectomized sham-operated
animals. Estrogen treatment led to lower creatinine con-
centration, but only after estriol treatment urea concen-
tration were also significantly lower (Table 2).
Morphologic investigations
Quantitative morphology of the myocardium. Capil-
lary length density was significantly lower (P < 0.05)
and mean intercapillary distance significantly higher in
vehicle-treated uninephrectomized/ovariectomized rats
compared to sham ovariectomized-operated controls and
17-b-3-benzoate estradiol or estriol-treated uninephrec-
tomized/ovariectomized animals (Table 3, Fig. 1).
The volume density of capillaries was signifi-
cantly lower in vehicle-treated uninephrectomized/ovari-
ectomized animals compared to sham-ovariectomized
animals. Estradiol prevented the decrease of this param-
eter significantly, and estriol even normalized it.
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Fig. 1. Capillary supply in a vehicle-treated uninephrectomized/sham ovariectomized rat. (A) Normal appearance. (B) Reduced density of capillary
profiles and expansion of the nonvascular interstitium is clearly visible in the myocardium of a vehicle-treated uninephrectomized/ovariectomized
rat. Myocardium of uninephrectomized/ovariectomized animals treated with estriol (C) or estradiol (D) with almost normal myocardial capillary
density (semithin sections, magnification 1:1200).
The volume density of the interstitial tissue was signifi-
cantly higher in vehicle-treated uninephrectomized/
ovariectomized animals compared to sham-
ovariectomized animals and was significantly lower
after 17-b-3-benzoate estradiol and by estriol treatment.
Quantitative morphology of intramyocardial arterioles
and of the aorta. The lumen diameter of intramyocar-
dial arterioles was not significantly different between the
groups (Table 4). The wall thickness and the wall-to-
lumen ratio of intramyocardial arteries were increased
in all uninephrectomized-operated animals compared to
sham animals. None of the interventions showed signifi-
cant improvement.
The wall thickness of the aorta was signifi-
cantly elevated in vehicle-treated uninephrectomized/
ovariectomized animals, but none of the estrogens was
effective.
Immunohistochemical investigations
In the heart expression of ET-1 on the protein level
was significantly (P < 0.05) higher in the uninephrec-
tomized/ovariectomized + vehicle (0.76 ± 0.07) than
in controls (0.14 ± 0.11) (see Fig. 2). It was sig-
nificantly lower in 17-b-3-benzoate estradiol (0.12 ±
0.12) and estriol (0.19 ± 0.06) treated uninephrec-
tomized/ovariectomized animals.
Protein expression of TGF-b was significantly (P <
0.05) higher in vehicle-treated uninephrectomized/
ovariectomized rats compared to uninephrectomized/
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Table 4. Measurements of intramyocardial arterioles and of the aorta thoracica descendens
Lumen diameter of Wall thickness of Wall-to-lumen ratio Lumen Wall Wall-to-
intramyocardial intramyocardial of intramyocardial diameter of thickness of lumen
arteries lm arteries lm arteries the aorta mm the aorta mm ratio ×102
Uninephrectomy/sham ovariectomy +
vehicle (N = 9)
29.3 ± 2.33 4.47 ± 0.91a,b,c 0.15 ± 0.04a,b,c 1.69 ± 0.08a 0.13 ± 0.01a 7.86 ± 0.69
Uninephrectomy/sham ovariectomy +
17-b-3-benzoate estradiol (N = 10)
29.4 ± 2.00 5.64 ± 0.75a,b 0.19 ± 0.03a,b,c 1.66 ± 0.05a 0.13 ± 0.01a 7.61 ± 0.77
UNX/OVX + vehicle (N = 10) 28.8 ± 2.16 7.23 ± 0.29a 0.25 ± 0.02 1.74 ± 0.05 0.15 ± 0.03 8.56 ± 1.69
Uninephrectomy/ovariectomy +
17-b-3-benzoate estradiol (N = 11)
27.7 ± 2.79 6.69 ± 0.78 0.24 ± 0.02 1.68 ± 0.10 0.14 ± 0.01 8.52 ± 0.92
Uninephrectomy/ovariectomy + estriol
(N = 9)
27.0 ± 2.49 6.37 ± 0.80 0.24 ± 0.02 1.67 ± 0.16 0.14 ± 0.01 8.46 ± 0.82
Analysis of variance (ANOVA) NS P < 0.05 P < 0.05 P < 0.05 P < 0.05 NS
aP < 0.05 vs. uninephrectomy/ovariectomy + vehicle; bP < 0.05 vs. uninephrectomy/ovariectomy + 17-b-3-benzoate estradiol; cP < 0.05 vs. uninephrec-
tomy/ovariectomy + estriol.
sham rats (0.08 ± 0.06) (see Fig. 3). In both estrogen-
treated groups the expression was lower (17-b-3-
benzoate estradiol 0.19 ± 0.05; estriol 0.22 ± 0.05).
The protein expression of the a-estrogen receptor
protein was not significantly different between vehicle-
treated uninephrectomized/ovariectomized (0.5 ± 0.4)
and uninephrectomized/sham (0.26 ± 0.25). But
treatment with 17-b-3-benzoate estradiol uninephrec-
tomized/ovariectomized (1.6 ± 0.6) and estriol (1.4 ± 0.6)
increased the expression significantly (P < 0.05).
The protein expression of VEGF was not significantly
different between uninephrectomized/sham (0.28 ± 0.19)
and vehicle-treated uninephrectomized/ovariectomized
animals (0.45 ± 0.19). 17-b-3-benzoate estradiol (1.1 ±
0.24) and estriol (0.9 ± 0.19) increased VEGF expression
significantly.
The protein expression of the VEGF receptor Flt-1 was
not significantly different between uninephrectomized/
sham (0.52 ± 0.29) and vehicle-treated uninephrec-
tomized/ovariectomized animals (0.61 ± 0.25). Both es-
trogens increased the protein expression of Flt-1 signif-
icantly. In this respect estriol was more effective (2.2 ±
0.32) than 17-b-3-benzoate estradiol (1.23 ± 0.34).
The expression of eNOS protein was not significantly
different between uninephrectomized/sham (0.52 ± 0.29)
and vehicle-treated uninephrectomized/ovariectomized
(0.61 ± 0.25). 17-b-3-benzoate estradiol (1.23 ± 0.34)
and estriol (2.16 ± 0.32) increased eNOS expression
significantly.
Semiquantitative RT-PCR for cardiac ET-1 and TGF-b
mRNA expression
The expression of ET-1 mRNA in the heart
was significantly higher in vehicle-treated uninephrec-
tomized/ovariectomized rats (1.4 ± 0.23) compared to
control uninephrectomized/sham rats (0.86 ± 0.09). Car-
diac ET-1 mRNA expression was significantly lower (P <
0.05) in 17-b-3-benzoate estradiol-treated uninephrec-
tomized/ovariectomized rats (1.09 ± 0.02) and estriol-
treated rats (1.07 ± 0.1).
In parallel, the expression of TGF-b mRNA in
the heart was significantly higher (P < 0.05) in 17-b-
3-benzoate estradiol-treated uninephrectomized/
ovariectomized rats (1.0 ± 0.01) and vehicle-treated
uninephrectomized/ovariectomized rats (0.9 ± 0.02)
compare to vehicle-treated uninephrectomized/sham
control rats (0.7 ± 0.03) and estriol-treated uninephrec-
tomized/ovariectomized animals (0.6 ± 0.04).
DISCUSSION
The study documents that in SHRsp rats with moderate
impairment of renal function estrogens prevent cardiac
damage (i.e., reduced capillary supply as well as increased
heart weight and width of interstitium). Although this was
not the primary purpose of the study, we also noted strik-
ing improvement of albuminuria with estrogens. Blood
pressure and serum creatinine concentrations were not
significantly affected by estrogen treatment. Therefore,
in contrast to previous studies in spontaneously hyper-
tensive rats, we can dissociate the effect of estrogens on
heart weight and structure from blood-pressure effects
[24]. Although positive effects of estrogen or selective es-
trogen receptor modulators (SERM) on lipid blood levels
are known [25], serum cholesterol serum and low-density
lipoprotein (LDL) cholesterol levels were not affected
by estrogen treatment in the present study, but this point
has little relevance, since rodents are high high-density
lipoprotein (HDL) animals with a lipid spectrum strik-
ingly differing from that of primates. Therefore, they fail
to spontaneously develop atherosclerotic lesions.
In uninephrectomized SHRsp a significantly lower cap-
illary supply was noted compared to sham op. What
are the implications of the reduced capillary density in
the heart of untreated SHRsp rats? The associated in-
crease of intercapillary distance will presumably compro-
mise blood and oxygen supply of cardiomyocytes, at least
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Fig. 2. Immunohistological staining with
endothelin-1 (ET-1). Expression of ET-1 on
the protein level was significantly higher in
uninephrectomized/ovariectomized + vehicle
(B) compared to uninephrectomized/sham-
ovariectomized (A), and estradiol (D) and
estriol (C) treated uninephrectomized/
ovariectomized animals (magnification
1:400).
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Fig. 3. Imunohistologic staining with
transforming growth factor-b (TGF-b).
Expression of TGF-b on the protein level
was significantly higher in uninephrec-
tomized/ovariectomized + vehicle (B)
compared to uninephrectomized/sham-
ovariectomized (A), and estradiol (D) and
estriol (C) treated uninephrectomized/
ovariectomized animal (magnification 1:400).
under conditions of increased demand. In contrast to our
results Lamping, Christensen, and Tomanek [26] did not
detect any impairment of capillary density with estro-
gen treatment in either normal or ischemic tissue in rab-
bits. It is problematic, however, to directly compare the
results because species, duration of the experiment, as
well as dose and mode of administration of estrogens
were different in the two studies. The changes in capil-
lary density by estrogens in our study were associated
with similar changes in expression of VEGF, supporting
the suggestion that estrogens directly regulate transcrip-
tion or stability of the gene of VEGF [27], its receptor
flk-1 [28–31], of basic fibroblast growth factor (bFGF)
[32] and of NOS [33], as confirmed by some orientat-
ing immunohistochemical investigations in the present
study.
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The effects of estrogens on capillary structure are
complemented by beneficial effects on endothelial cell
function. Estradiol stimulates the expression of eNOS
in vascular cells [34, 35] and stimulates nitric oxide–
dependent vasodilatation in vivo [36]. In the present
study both estrogen interventions increased eNOS
mRNA expression. Mechanistic studies demonstrated
the ability of estrogens to increase the bioavailability of
nitric oxide by directly stimulating changes in the expres-
sion of eNOS or through indirect regulation of genes en-
coding essential cofactors. In addition, estrogen may alter
nitric oxide synthesis via its direct antioxidant effects [37].
Another target of estrogen is ET-1, a potent vaso-
constrictor peptide with mitogenic effects on smooth
muscle cell growth. Estrogens decrease plasma ET-1 in
postmenopausal women, but the effects of estrogens on
ET-1 production in the human female coronary circu-
lation are unknown [11, 38]. Estrogens modulate ET-
1–mediated vascular responses in deoxycorticosterone
acetate (DOCA)-salt hypertension [39]. In our study
expression of ET-1 on the protein level was increased
in vehicle-treated ovariectomized animals and staining
for ET-1 was reduced by both estrogen interventions. 2-
hydroxyestradiol and 2-methoxyestradiol are more po-
tent inhibitors of ET-1 synthesis than estradiol suggesting
an important role of estradiol metabolites for the cardio-
vascular protective effects of estrogens [40, 41].
ERa and ERb are expressed in vascular endothelial
cells [42]. In a previous study Pare et al [43] showed in
ERa and ERb knockout mice with vascular lesions that
the vasculoprotective effects of estrogens are mediated
by the ERa receptor. Our study does not provide infor-
mation on the relative roles of the ERa or ERb pathways,
but it is interesting that in the present study the expres-
sion of myocardial and vascular ERa was significantly
increased by estrogen treatment.
Exogenous estrogens clearly inhibit progression of
atherosclerotic lesions in numerous animal models
of atherosclerosis [44–46]. Several studies in animals
showed atheroprotection with estradiol was seen at doses
that did not alter the lipid profile [47]. Estrogens reduce
LDL oxidation and recent studies showed that estriol
must be metabolized to prevent LDL oxidation [48, 49].
In our study LDL levels were high in all ovariectomized
animals, and none of the interventions decreased LDL
levels. As outlined above, the rat is a poor model for lipid
changes in humans.
In the present study estrogens failed to prevent pathol-
ogy of arteries (wall thickness of intramyocardial arter-
ies and of the aorta). Data on the vascular effects of
estrogens are controversial. Estrogen treatment increases
aortic stiffness and potentiates endothelial vasodilatation
function in hindquarters, but not in carotid vascular bed
[50], suggesting considerable regional and species vari-
ability [1, 51].
CONCLUSION
In the present rat model of moderate renal insufficiency
the two different estrogens studied had beneficial effects
on heart weight and cardiac structure. Whether the results
can be extrapolated to other species remains to be seen.
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